A randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers for treatment of fungal infections
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs VL 2397 (Primary)
- Indications Mycoses
- Focus Adverse reactions; First in man
- 02 May 2017 Results from this trial will be presented at the ASM Microbe 2017 conference, according to a Vical media release.
- 09 Mar 2017 Status changed from recruiting to completed, according to a Vical media release.
- 09 Mar 2017 According to a Vical media release, full data will be presented at an upcoming scientific conference in 2017.